SR BioPharma Pte. Ltd. was established in Singapore by SR BioPharma (Hainan) Group Co., Ltd. (SRP). The company focuses on the research, development, and commercialization of innovative anti-HPV technologies and products, with a commitment to developing new approaches to persistent high-risk human papillomavirus (hrHPV) infection, reducing the risk of HPV-related diseases and cervical cancer, and protecting women’s health.

SRP is a biotechnology company dedicated to innovative biopharmaceutical R&D and commercialization. Established in the Medical Valley of Haikou, China, in 2006, SRP traces its research activities back to a research institute founded in Maryland, USA, in 2000.

SRP established two subsidiaries in China Medical City, Taizhou, in 2013, a marketing center in Hong Kong in 2019, and SR BioPharma Pte. Ltd. in Singapore in 2022, building an international R&D and commercialization network.

For more than 20 years, SRP has focused on HPV infection and related diseases. Targeting key mechanisms underlying persistent hrHPV infection, SRP has developed a proprietary molecularly targeted anti-HPV technology and the REBACIN® series of anti-HPV products.

Together, these efforts have built an integrated innovation platform spanning basic research, mechanism-of-action studies, product development, clinical research, real-world evidence generation, and commercialization.